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Abstract: The objective of this study was to determine plasma pharmacokinetics and 
bioavailability of fenbendazole (FBZ) and oxfendazole (OFZ) after intravenous (iv) and oral 
administrations of FBZ (5 mg/kg) to alpacas. Plasma concentrations of FBZ and OFZ after 
administration of FBZ iv and orally (5 mg/kg) were determined by high-performance liquid 
chromatography with ultraviolet detection. Total clearance (CL) of FBZ was 16.5±4 mL/kg/min 
(range: 4–31 mL/kg/min), and steady-state volume of distribution (Vd
ss
) was 3.3±1 L/kg (range: 
1.7–7.4 L/kg). The terminal phase half-life of FBZ after iv administration was 5.9±3.8 hours 
(range: 0.8–20 hours). After oral administration, the FBZ terminal phase half-life was 
23±5 hours (range: 9–37 hours) and the systemic bioavailability of FBZ was 16%±6% (range: 
1%–41%). Peak FBZ concentrations after oral administration were 0.13±0.05 µg/mL (range: 
0.05–0.28 µg/mL) at 10 hours (range: 8–12 hours). Peak plasma OFZ concentrations after oral 
dosing with FBZ (5 mg/kg) were 0.14±0.05 µg/mL (0.05–0.3 µg/mL) at 24±7 hours (range: 
12–48 hours). FBZ clearance is lower in comparison to that of other species. Systemic avail-
ability of FBZ after oral administration is low after oral dosing. Metabolites of FBZ produced 
by alpacas are similar to those observed in other species.
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Introduction
South American camelids are considered minor species by the US Food and Drug 
Administration’s Center for Veterinary Medicine.1 As such, there are few medications 
approved for use in these species. In spite of the paucity of drugs tested and approved 
for use in camelids, many medications are nonetheless used in alpacas with doses 
extrapolated from other species. Interspecies extrapolation is problematic because 
appropriate dosing in one species may result in toxicity, treatment failure, or both 
in another.1,2 Limited knowledge of South American camelid drug disposition and 
metabolism remains a concern when recommending benzimidazole anthelmintics for 
parasitism.3 Furthermore, the common use of benzimidazoles in alpacas is currently 
associated with significant anthelmintic resistance.4
Gastrointestinal parasitism is a common problem in camelids. South American 
camelids are susceptible to gastrointestinal parasitism and develop clinical signs such 
as anorexia, weight loss, anemia, and hypoproteinemia similar to small ruminants and 
cattle. Parasites commonly encountered include Trichostrongyle spp (Haemonchus 
spp, Ostertagia spp, and Trichostrongylus spp), Nematodirus spp, Capillaria spp, 
and Trichuris spp.5
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Of the gastrointestinal parasites, Nematodirus spp 
and Trichuris spp demonstrate limited susceptibility to 
avermectin-type anthelmintics.5 Trichuris spp also display 
limited susceptibility to benzimidazoles, with the exception 
of oxibendazole and oxfendazole.5 As such, it is common 
to recommend appropriate benzimidazole anthelmintics 
for use in anthelmintic programs to prevent parasitism 
with benzimidazole-susceptible Trichostrongylid,  Trichuris 
spp, and aberrant migration of the meningeal worm, 
 Parelaphostrongylus tenuis. Veterinarians working with 
South American camelids commonly recommend the use 
of anthelmintics on a monthly, or bimonthly, basis for the 
treatment of aberrant migration of the meningeal worm 
 (Parelaphostrongylus tenuis) in animals cohabitating with 
white tail deer (Odocoileus virginianus). The use of a benz-
imidazole anthelmintic has been recommended in rotational 
systems due to the incidence of nematodes demonstrat-
ing limited susceptibility to the avermectin anthelmintics 
(Nematodirus spp, Trichuris spp.).
A previous study demonstrated absorption of FBZ after 
oral administration of .5 mg/kg to ,10 mg/kg FBZ paste 
(Safe-Guard® paste, 10%; Intervet International, Millsboro, 
DE, USA) in llamas.6 Their studies demonstrate that plasma 
concentrations achieved in llamas after oral dosing with the 
paste dewormer were suitable for treatment of Nematodirus 
spp., Strongyloides spp., and Trichuris spp. and were compara-
ble to those observed in other species studied.7 However, there 
are no reports describing the plasma concentrations of FBZ 
metabolites, of which OFZ is important due to its anthelmintic 
activity and higher potency against inhibited Trichostrongyle 
stages, lungworms, and Trichuris spp parasites.5
The purpose of this study was three fold: 1) to describe 
the plasma disposition of fenbendazole (FBZ) after intrave-
nous (iv) (5 mg/kg) and oral (5 mg/kg) dosing in alpacas; 
2) to determine sequential metabolism of FBZ in alpacas by 
quantitation of plasma concentrations of the FBZ-related 
compound oxfendazole (OFZ) and to identify OFZ–sulfone 
after oral dosing; 3) to determine fractional absorption of 
FBZ. The doses chosen for this study were those studied in 
llamas and approved for cattle (5 mg/kg).6
Materials and methods
alpacas
Five healthy alpacas of mixed age (ages 6.7±2.2 years) and 
sex (male =2; female =3), weighing 67.2±10.3 kg were 
used in this study. Animals were part of a small research 
herd maintained at The Ohio State University Veterinary 
Medical Center. Before initiation of the study, the animals 
were housed in pens in accordance with and approved by 
the Institutional Laboratory Animal Use and Care protocol. 
Animals were healthy based upon physical examination, 
complete blood counts, and serum biochemical panel. The 
animals had not received any drugs for a minimum of 4 weeks 
before initiation of the study.
For iv dosing, a small area of their neck was clipped and 
prepared for aseptic placement of two iv catheters, one in 
each jugular vein. A sterile 5.25-inch Teflon-coated catheter 
was placed into each jugular vein, one for iv dosing and one 
for periodic blood sampling. The catheters were covered with 
sterile 10 cm × 10 cm gauze pads and wrapped with elastic 
bandage material. The catheters were flushed before and 
immediately after blood sample removal with heparinized 
saline to prevent clotting throughout the study periods.
For oral dosing, one jugular catheter was placed asepti-
cally in the right jugular vein for periodic sampling of blood. 
The catheters were managed and the samples obtained as 
described above for iv dosing.
animal dosing
For the iv study, five animals (two male and three female) 
were randomly assigned to be dosed by iv administration 
of FBZ in propylene glycol/dimethyl sulfoxide (DMSO) 
(6% FBZ solution in a 80:20 propylene glycol/DMSO 
mixture; 5 mg/kg body weight). For the oral dosing study, 
FBZ was administered at 5 mg FBZ/kg body weight per os as 
a 10% FBZ suspension (n=5; Safe-Guard®, Suspension, 10% 
FBZ; Intervet International, Millsboro, DE, USA). Those ani-
mals receiving iv administration first were followed 2 weeks 
later by oral dosing, whereas, those receiving oral administra-
tion first were followed 2 weeks later by iv dosing.
animal sampling
Before dosing, heparinized blood was obtained from all 
animals to serve as negative control plasma (time =0). 
After iv dosing, heparinized blood samples were taken at 
3 minutes, 6 minutes, 12 minutes, 18 minutes, 30 minutes, and 
45 minutes; and at 1 hour, 1.5 hours, 2 hours, 2.5 hours, 
3 hours, 3.5 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 
12 hours, 24 hours, 48 hours, and 96 hours postdosing from the 
contralateral catheter. After oral dosing of 10% oral suspension 
(5 mg FBZ/kg body weight), heparinized blood samples were 
taken at 0.5 hour, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 
24 hours, 48 hours, and 96 hours postdosing. Plasma samples 
were maintained cold on ice until centrifugation at 1,000× g 
for 10 minutes at 4°C. Plasma was removed and stored in 
duplicate 1.5 mL cryovials at -20°C until analysis.
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Drug analysis
A full description is presented in Supplementary materials.
Plasma concentration versus time data from each 
animal given FBZ iv (5 mg/kg; n=5) were subjected to 
compartmental analysis (Pharsight Corporation, Phoenix 
WinNonlin professional, version 6.3; St Louis, MO, USA). 
The number of exponential terms required to describe the 
serum concentration versus time data for each animal was 
determined by evaluation of concentration versus time 
curves, applying Akaike’s information criterion and exami-
nation of residuals.8
A full description of data analysis is presented in Supple-
mentary materials.
Results
chromatography
The high-performance liquid chromatography (HPLC) 
method used in this study was suitable for the determination 
of FBZ and OFZ in alpaca plasma, with a limit of quantita-
tion (LOQ) for FBZ of 50 ng/mL. The modifications we 
made to the mobile phase, in combination with the analytical 
column, resulted in symmetrical peaks with adequate peak 
height, resolution, and retention time (RT) of both FBZ 
and OFZ for evaluation of FBZ and related compounds 
in alpacas.9 This method was of sufficient analytical selec-
tivity and sensitivity to quantitate plasma concentrations of 
FBZ and OFZ in alpacas dosed with iv and oral forms of this 
anthelmintic. This was determined by complete resolution 
of FBZ (RT =13.5 minutes) and related compounds OFZ 
(RT =5.75 minutes) and FBZ-sulfone (RT =7.6 minutes) and 
no interference with other compounds eluting from plasma. 
Standard curves were linear over the range of concentra-
tions analyzed (0.05 µg/mL–8.0 µg/mL), with correlation 
coefficients for FBZ of 0.998 (range: 0.990–0.999) and 
OFZ of 0.998 (range: 0.993–0.999). The limit of detection 
(LOD) (0.025 µg/mL) and LOQ (0.05 µg/mL) for FBZ, LOD 
(0.0125 µg/mL) and LOQ (0.025 µg/mL) for OFZ, and the 
magnitude of drug recovery (81% for FBZ; 74% for OFZ) 
were suitable for this analysis. The between- and within-day 
accuracy values were ,15% (range: 1.4%–14.5%) at the 
three concentrations tested, and the between- and within-day 
precision values were ,15% (range: 3%–11.9%) over the 
range of concentrations tested.
Plasma concentration versus time
Mean plasma FBZ and OFZ concentrations after iv adminis-
tration of FBZ (5 mg/kg body weight) to alpacas are depicted 
graphically in Figure 1. The concentration–time data for 
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Figure 1 Plasma concentrations of FBZ and OFZ in alpacas after iv administration 
of FBZ in a DMsO/propylene glycol vehicle.
Notes: Mean ± seM values for the plasma concentrations of FBZ (—•—) and OFZ 
(——) after iv administration of FBZ in DMSO/propylene glycol (50 mg/mL) to five 
alpacas. inset: Plasma concentration versus time curve of OFZ after iv administration 
of FBZ on an enlarged scale to demonstrate the appearance of OFZ.
Abbreviations: DMsO, dimethyl sulfoxide; FBZ, fenbendazole; iv, intravenous; 
OFZ, oxfendazole; seM, standard error of the mean.
individual animal iv drug dosing were best described using a 
biexponential equation corresponding to a two-compartment, 
open pharmacokinetic model. Pharmacokinetic parameters 
for FBZ derived from two-compartment analysis of alpaca 
plasma concentration–time data are presented as median 
(range) in Table 1. Plasma concentration versus time data 
for FBZ by oral administration (5 mg/kg FBZ) are presented 
graphically in Figure 2. The results of the noncompartmental 
statistical moment analysis of plasma concentration versus 
time data after oral dosing of FBZ are summarized in Table 2. 
In addition, selected pharmacokinetic parameters for OFZ 
are also provided (Table 2).
Injection of FBZ dissolved in propylene glycol/
DMSO resulted in mild hemolysis, which was apparent 
for approximately 30 minutes after iv injection of FBZ in 
three of five animals (mild hemoglobinemia). Estimated 
maximum plasma concentrations calculated by the model 
for FBZ were 11.3±1 µg/mL (range: 8–15.5 µg/mL). The 
concentration of FBZ in plasma decreased rapidly for the 
initial 1.5 hours postadministration of the iv drug. Plasma 
concentrations exceeded the LOQ for 24 hours postdos-
ing. The area under the concentration–time curve for FBZ 
(AUC
FBZ
) after iv administration was 7.7±2.5 µg × h/mL 
(range: 2.7–20 h × µg/mL), area under the first moment curve 
was 92±72 h2 × µg/mL (range: 2–376 h2 × µg/mL), and mean 
residence time (MRT) was 7±4 hours (range: 2–19 hours). 
The elimination half-life of FBZ from plasma after iv 
administration was 5.9±3.8 hours (range: 0.8–21 hours). The 
median plasma clearance of FBZ normalized to body weight 
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Table 1 Pharmacokinetic analysis of fenbendazole after iv dosing 
in a DMsO/propylene glycol vehicle
Parameters Units Mean ± SEM Range
a µg/ml 9.8±1 7–13.7
α h-1 16±5 2.3–32.2
B µg/ml 1.4±0.3 0.42–2.3
β h-1 0.4±0.15 0.03–0.9
Cpmax µg/ml 11.3±1 8.2–15.5
k10 h-1 2.5±0.9 0.5–4.8
k12 h-1 11.8±3.9 1.5–24
k21 h-1 2.5±0.7 0.2–4.8
cl ml/min/kg 16.5±4.4 4–31
Vss ml/kg 3,345±1,042 1,713–7,433
T1/2k10 hour 0.6±0.2 0.15–1.0
T1/2α hour 0.1±0.05 0.02–0.3
T1/2β hour 5.9±3.8 0.8–21
aUc h µg/ml 7.7±2.5 2.7–20
aUMc h2 µg/ml 92±72 2–376
MRT hour 7±4 2–19
Notes: Plasma concentration versus time data best fit a two-compartment model. 
The two-compartment open model for the pharmacokinetic analysis of plasma 
fenbendazole concentration versus time data after iv administration of 5 mg/kg 
fenbendazole in DMSO:propylene glycol to five alpacas is shown. Raw concentration 
versus time data were weighted 1/y2 before analysis. A and B are the zero-time 
intercepts of the concentration axis and represent the extrapolated plasma 
concentrations for the distribution and elimination phases, respectively. The macro 
rate constants are α (distribution), β (elimination), and half-lives (T1/2α and T1/2β) of 
distribution and elimination, respectively. Cpmax is the maximum concentration (a + B). 
k10 is the rate at which the drug leaves the body from the central compartment. 
The first-order rate constants k12 and k21 denote the rate of change from the 
central compartment to the peripheral compartment (k12) and from the peripheral 
compartment back to the central compartment (k21); cl is total clearance; Vss is 
the volume of distribution at steady state. also listed are the area under the curve 
(aUc), area under the moment curve (aUMc), and mean residence time (MRT).
Abbreviations: DMsO, dimethyl sulfoxide; iv, intravenous; seM, standard error 
of the mean.
Table 2 statistical moment analysis of FBZ and OFZ in alpacas 
after oral administration of FBZ suspension (5 mg/kg)
Parameter Mean ± SEM (range)
FBZ OFZ
aUc (h µg/ml) 6±2.6 (0.7–14) 8±3 (0.7–19)
Percentage of  
total aUc
47±7 (32–65) 53±7 (35–68)
T1/2λz (hours) 23±5 (9–37) na
MRT (hours) 39±7 (17–54) 40±4.8 (31–58)
Cmax (µg/ml) 0.12±0.05 (0.05–0.28) 0.14±0.05 (0.05–0.31)
Tmax (hours) 9.6±1 (8–12) 24±6.6 (12–48)
F (%) 15±6 (1–41) na
Notes: noncompartmental statistical moment analysis of FBZ and OFZ in the 
sera of five alpacas after oral administration of fenbendazole (5 mg/kg). T1/2λz is the 
terminal-phase half-life; Tmax is the time to achieve Cmax; Cmax is the maximum plasma 
concentration. aUc was calculated from the concentration versus time curve using 
the trapezoidal rule and extrapolated to infinity. For FBZ, the AUC was extrapolated 
to infinity using the last-measured concentration divided by λz (the slope of the 
terminal phase of the curve using at least three time points). For OFZ, aUc was 
calculated to the last-measured plasma concentration. Mean residence time (MRT, 
in hours) was calculated using aUMc/aUc. F% represents the fractional absorption 
of FBZ after oral administration.
Abbreviations: aUc, area under the concentration versus time curve; FBZ, 
fenbendazole; na, not applicable; OFZ, oxfendazole; seM, standard error of the mean; 
aUMc, area under the moment curve. 
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Figure 2 Plasma concentrations of FBZ and OFZ in alpacas after oral administration 
of FBZ suspension.
Notes: Mean ± seM values for the plasma concentrations of FBZ (—•—) and OFZ 
(——) after oral administration (5 mg/kg) of FBZ.
Abbreviations: FBZ, fenbendazole; OFZ, oxfendazole; seM, standard error of the 
mean.
was 16.5±4.4 mL/min/kg (range: 4–31 mL/min/kg). The 
steady-state volume of  distri bution (Vd
ss
) was 3.3±1.0 L/kg 
(range: 1.7–7.4 L/kg).
Mean plasma concentrations of OFZ after iv dosing of 
FBZ were greater than the LOQ by 6 minutes postinjection. 
Mean maximum plasma concentration (C
max
) observed for 
OFZ after iv dosing with FBZ was 0.39±0.1 µg/mL (range: 
0.2–0.79 µg/mL) at 5 hours (range: 4–10 hours) postdosing. 
Plasma OFZ concentrations were quantifiable up to 48 hours 
after iv dosing. The AUC for OFZ after iv administration of 
FBZ (13.6±4 h µg/mL; range: 6.3–17.5 h µg/mL) was similar 
to that observed for FBZ. The MRT determined for OFZ was 
30±5 hours (range: 17–52 hours).
Combining the AUC for FBZ and OFZ after iv administra-
tion, the percentage of total drug AUC, after iv administration 
for FBZ (AUC
FBZ
) comprised 46%±11.5% (range: 33%–64%) 
and AUC
OFZ
 comprised 54%±11.5% (range: 33%–64%). 
After oral dosing of alpacas with FBZ, the AUC
FBZ
 and 
AUC
OFZ
 were 6±2.3 h µg/mL (range: 0.7–14 h µg/mL) and 
7.8±3 h µg/mL (range: 0.65–19 h µg/mL) respectively. 
The percentage of the total AUC for FBZ + OFZ as AUC
FBZ
 
was 49%±5% (39%–71%) and AUC
OFZ
 was 50%±5% (range: 
29%–61%). The terminal phase half-life (T
1/2
) of FBZ after 
oral administration was 23±5 hours (range: 9–37 hours) 
whereas the MRT was 39±7 hours (range: 17–54 hours). 
Maximum plasma concentrations of FBZ and OFZ after 
oral dosing with FBZ were 0.13±0.05 µg/mL (range: 0.05–
0.28 µg/mL) and 0.14±0.05 µg/mL (range: 0.05–0.31 µg/
mL), respectively. Systemic availability of FBZ after oral 
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administration of FBZ was 36% (range: 11%–148%). 
However, when corrected for prolonged half-life after oral 
administration, the total systemic availability was 15%±6% 
(1%–41%).
Identification of unknown metabolite in alpaca plasma 
after iv and oral administrations of FBZ was performed to 
assist in the identification of an unknown peak that appeared 
later in the concentration versus time course in alpacas. On 
the basis of the RTs, and comparisons among the molecular 
masses of FBZ (RT =13.5 minutes; molecular weight: 299.4 g/
mole), OFZ (RT =5.75 minutes; molecular weight: 315.35 g/
mole), and the unknown compound (RT =7.6 minutes; 
molecular weight: 331.35 g/mole) prepared by isolation of 
individual HPLC fractions, the minor metabolite is compat-
ible with FBZ sulfone.
Discussion
Some alpacas demonstrated hemolysis after iv administration 
of FBZ (5 mg/kg) when solubilized in a DMSO/propylene 
glycol vehicle. Although there were no clinically evident 
effects of this hemolysis and the occurrence of hemolysis was 
evident only for 30 minutes after administration, we believe 
this was due to administration of the drug rapidly in a DMSO/
propylene glycol vehicle. There may have been other causes 
leading to hemolysis because other studies evaluating iv 
 dosing of benzimidazoles did not report adverse reactions.10,11 
Peak plasma concentrations of FBZ after iv administration 
were 6.2±0.74 µg/mL (range: 3.5–7.2 µg/mL). FBZ remained 
above the LOQ in plasma for 24 hours in all five alpacas (C
last
: 
0.23±0.07 µg/mL; range: 0.15–0.53 µg/mL). In contrast, after 
iv administration to swine, FBZ was only detected to 6 hours 
postadministration, although they were limited to 1 mg/kg 
doses due to intolerance associated with iv formulation.10
The FBZ AUC was best described by a two-compartment 
open model. Primary pharmacokinetic parameters (CL, 
Vd) after iv administration of FBZ to alpacas demonstrated 
moderate rates of CL and a wide Vd. Plasma CL reflects con-
tribution of the drug’s metabolism and elimination processes 
and is directly dependent on the volume of distribution of a 
drug within an animal.12 The plasma CL of FBZ in alpacas 
is lower than that reported for swine, but greater than that 
reported for cattle, goats, and rabbits.10,13 The steady-state Vd 
of FBZ after iv administration to alpacas is comparable to 
the values reported for cattle, goats, and swine.10,13 Similar 
to the distribution in other species, FBZ is widely distributed 
in alpacas after iv administration.
Plasma concentrations of FBZ-sulfoxide (OFZ) after 
iv administration, in two of the five animals, were greater 
than the LOQ at 3 minutes and the compound was observed 
in all five animals by 6 minutes. In swine, plasma concen-
trations of OFZ were detected at the first sampling time 
point (2 minutes) after iv administration of FBZ (5 mg/kg). 
Maximum plasma OFZ concentrations (0.3±0.1 µg/mL; 
range: 0.2–0.79 µg/mL) were observed 6 hours postdosing. 
Peak OFZ concentration in alpacas occurred later than in 
swine after iv administration of FBZ, but at approximately 
the same time after iv administration of FBZ to goats and 
cattle.10,14,15 After iv administration of FBZ, metabolism of 
FBZ to sulfoxide metabolites occurs rapidly in most species. 
The rapid appearance of OFZ after iv administration of FBZ, 
followed later by the appearance of FBZ-sulfone, is reflective 
of the conversion of the parent drug (FBZ) into the oxida-
tion products (OFZ, then FBZ sulfone), as demonstrated in 
swine and sheep.10,16
A single iv dose of FBZ in propylene glycol/DMSO was 
associated with a plasma terminal phase half life (T
1/2
) of 
5.9±3.8 hours (range: 0.8–21 hours) and MRT of 7±4 hours 
(range: 2–19 hours). The terminal phase half-life (T
1/2
) of 
FBZ after iv administration to alpacas is similar to that in 
goats and rabbits, shorter than that in cattle and catfish, but 
greater than that observed for swine, chickens, and turkeys.13 
Rapid reduction of plasma concentration of FBZ after iv 
administration reflects both the rate of elimination from the 
body and dependence upon the distribution of drug to tissues 
based upon drug physicochemical properties.
After oral administration of FBZ to alpacas (5 mg/kg), 
plasma concentrations of FBZ were .LOQ in four of five 
alpacas by 0.5 hours and in all alpacas by 2 hours. The 
maximum concentration of FBZ in alpacas was similar to 
that reported in sheep (10 mg/kg suspension) and cattle 
(4.5 mg/kg suspension) but greater than that observed in 
swine (5 mg/kg suspension) and horses (10 mg/kg granules). 
Of interest, peak plasma FBZ concentrations after oral dos-
ing of alpacas (5 mg/kg) were lower than those observed 
in llamas (6–9 mg/kg paste). As substantial variation in 
absorption of benzimidazoles has been reported depending 
upon retention within the gastric compartments, differences 
in peak plasma concentrations probably reflect, in part, the 
formulation administered to a particular species.17 It is likely 
that monogastric species retain FBZ for shorter periods of 
time than ruminants, leading to reduced drug absorption. 
 Suspension formulations reportedly traverse gastric com-
partments more rapidly than paste or pelletized formula-
tions, leading to lower C
max
 values.17 Likewise, ruminants 
may have prolonged absorption of drugs due to the large 
pregastric compartment. The camelid gastric compartment 
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has glandular regions that may improve absorption and the 
differences between alpacas and llamas may simply reflect 
the dose administered and the drug formulation.
OFZ was detectable after oral administration of FBZ 
to alpacas by 4 hours postdosing and C
max
 for OFZ was 
0.16 µg/mL at 24 hours. This pattern is similar to that reported 
in other species.10,13–15 While both FBZ and OFZ have 
antiparasitic activity, FBZ has greater affinity for parasite 
tubulin.18 Metabolism of the thiol benzimidazole (FBZ) to 
sulfoxide metabolites (OFZ) occurs rapidly in most species. 
The rapid appearance of OFZ after iv administration is well 
described in the literature and reflects the sulfoxidation of 
FBZ within the animal.10,18 However, the metabolic conver-
sion of FBZ to OFZ is reversible and has been documented 
in studies comparing systemic administration of FBZ and 
OFZ.18 Further, reductive metabolism of OFZ back to FBZ 
occurs within the rumen of sheep and cattle, suggesting 
interconversion of FBZ to OFZ and back, prolonging the 
anthelmintic activity of FBZ.16
The AUC for FBZ after iv administration to alpacas was 
greater than that observed in swine after iv dosing, whereas 
the AUC
FBZ
 in channel catfish was nearly double that observed 
in alpacas.11 The AUC reflects the drug exposure provided by 
a given dose. As has been suggested, the variability in pub-
lished studies (including differences in dosing), drug analysis 
methods, and metabolic fate of FBZ play important roles in 
the exposure to pharmacologically active species. Therefore, 
direct comparisons across species may not be appropriate due 
to differences in metabolic fate.18
The fractional absorption of FBZ after oral administration 
in alpacas was higher than that reported for other species 
studied.10,13 The higher bioavailability after oral administra-
tion was concerning because two of the animals demonstrated 
bioavailability .100%.13,18 Because bioavailability .100% 
has no practical meaning, we evaluated the fractional absorp-
tion (F) corrected for the prolonged half-lives of FBZ after 
extravascular administration in comparison to that after iv 
dosing. In these animals, half-life correction resulted in 
fractional absorption F being very similar to that reported in 
other studies (∼15%–20%). This suggests that bioavailability 
is absorption limited in alpacas.
In swine, the percentage of the total (FBZ + OFZ) AUC 
comprising FBZ is low (∼8%), whereas AUC
OFZ
 is ∼66% and 
AUC
FBZ-sulfone
 is 25% after iv administration of FBZ.10 Similar 
is the AUC
FBZ
 observed in sheep after oral administration of 
FBZ (7.8%) or OFZ (7.0%).16 In contrast, after FBZ admin-
istration to alpacas, the AUC
FBZ
 comprises approximately 
41%, while the AUC
OFZ
 is approximately 59%. This appears 
similar to that observed in cattle and goats wherein plasma 
concentrations of FBZ are higher and persist longer after 
FBZ dosing and have been shown to involve OFZ reduction 
to FBZ within the gastric compartment.14,15 While our study 
demonstrates a greater proportion of parent drug in plasma, 
the actual percentages are likely lower, based upon quantita-
tion of all metabolites. In spite of our inability to obtain a 
suitable reference standard containing purified FBZ sulfone, 
we were able to identify this metabolite in samples obtained 
after administration of FBZ to alpacas. The observations 
suggest that alpacas metabolize FBZ similar to that observed 
in other species.10,18
As suggested in the previous paragraph, quantitation of 
FBZ sulfone as well as iv administration of OFZ are two 
major limitations of this study. This information would prove 
useful in understanding the disposition and metabolism of 
benzimidazoles in camelids. On the basis of morphologic and 
physiologic differences of the camelid gastrointestinal tract, 
our results suggest substantial contributions of FBZ from cam-
elid fermentation compartments. The camelid first gastric com-
partment possesses substantial absorptive epithelium, reduced 
water content, and greater retention of feed in comparison to 
true ruminants.19 Absorption of drug by alpacas is probably 
dependent on the low solubility of FBZ and tendency for OFZ 
to be reduced to FBZ in the gastric compartment. Further, 
prolonged residence in the first gastric compartment, due to 
delayed emptying and nocturnal rumination, may play a role 
in the disposition of FBZ after administration to alpacas.
Conclusion
Differences in disposition and metabolism of FBZ in alpacas 
in comparison to the same processes in swine, sheep, and 
llamas were observed in this study. While the percentages 
of parent drug and metabolites differ between our study and 
those of others,10,18 the formation of sulfoxide and sulfone 
metabolites appears similar to that reported previously. 
The rates of metabolite formation and the interconversion 
of metabolites back to parent drug reflect differences in 
metabolism and gastrointestinal tract physiology of this 
species. Further evaluation of these phenomena in camelids 
would be useful clinically.
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Supplementary materials
apparatus
The LC apparatus consisted of an HPLC pump (Thermo 
Fisher Scientific, Dionex Bannockburn, IL, USA; 582 solvent 
delivery module), biocompatible autosampler (Thermo Fisher 
Scientific; 542 refrigerated), ultraviolet (UV) detector (Thermo 
Fisher Scientific; 580 dual channel, variable wavelength, 
UV/visible), thermal control column heater (Thermo Fisher 
Scientific). The UV detector was set to monitor 292 nm. The 
column was a C
18
, 250×4.6 mm, 5 µm particle size, reverse-
phase column (Grace Technologies, Deerfield, IL, USA).
chromatographic conditions
The mobile phase consisted of 0.01 M phosphoric acid 
(pH 4.0) and acetonitrile (60%:40%, v/v).1 The vacuum 
degassed and filtered (0.22 µm pore size filter) mobile phase 
was delivered at 1.0 mL/min. Column temperature was 
maintained at 35°C. Data were automatically collected and 
peaks identified and quantified using Coularray for Windows 
software (Version 2.0; Thermo Fisher Scientific).
Preparation of fenbendazole  
and oxfendazole stock solutions
Standards consisted of fenbendazole (FBZ; Sigma Chemi-
cal Co, St Louis, MO, USA; F5396) and oxfendazole (OFZ; 
Research Diagnostics Inc, Flanders, NJ, USA; 1483301). 
LC-grade acetonitrile, methyl-tert-butyl ether (m-tBE), and 
phosphoric acid were obtained from Thermo Fisher Scientific 
(St Louis, MO, USA). All other reagents were of HPLC grade. 
Ten milligrams of each drug was weighed quantitatively into 
individual 25 mL volumetric flasks. The drugs were then dis-
solved in 5 mL DMSO (100%) and further diluted by addition 
of acetonitrile to 25 mL. These two solutions (0.4 mg/mL; 
Standard A) were further diluted by placing 1.0 mL of each 
standard A in a 25 mL volumetric flask and diluting to 25 mL 
with acetonitrile (0.016 mg/mL FBZ and OFZ; Standard B). 
Appropriate volumes of A, B were added to 1.0 mL of blank 
alpaca plasma for preparation of a plasma FBZ/OFZ standard 
curve covering the range of 0.025 µg/mL to 8.0 µg/mL.
standard and sample preparation
Plasma from healthy alpacas (not study animals) that were 
not treated with FBZ or OFZ was used to prepare spiked 
plasma for development of standard curves. Plasma samples 
without added drug were prepared to serve as blank controls. 
A 200 µL volume of 0.1 N ammonium hydroxide was added 
to control and spiked plasma to increase pH.1 The samples 
were vortexed, and 5 mL of m-tBE was added to each tube, 
capped, and revortexed for 1 minute. Ether-containing 
samples were centrifuged at 1,000× g for 10 minutes at 4°C 
to separate the aqueous layer from ether layers. The m-tBE-
containing drug was removed, dried under nitrogen at 40°C 
and reconstituted with 1 mL mobile phase. The samples 
were vortexed for 30 seconds, and 500 µL was added to 
autosampler vials and capped. The samples were placed into 
autosampler tray and 50 µL injected onto chromatograph. 
Peak area of FBZ and OFZ in standards were determined and 
used for regression analysis to determine detector response 
per microgram of analyte. Samples from animals treated with 
the intravenous formulation and the 10% oral suspension 
were thawed, 1 mL aliquots placed into individual tubes, 
and 200 µL of 0.1 N ammonium hydroxide was added and 
vortexed. Drug was extracted with m-tBE as described within 
this standard and sample preparation section. All standards 
and samples were injected in triplicate. Individual standard 
curves were prepared daily for animal sample analysis. Peak 
areas were determined for OFZ and FBZ, and the peak areas 
were used to determine concentration of drug (compared to 
standard curve) and each concentration for replicate analysis 
was averaged. Samples that were below the limit of quantita-
tion (LOQ) on first analysis were reextracted, concentrated 
five-fold, and reanalyzed by HPLC.
Method validation
Standard curves prepared on each day of analysis were 
compared by determining the intercept, slope, r, and r2 using 
linear regression on six different days. Analyte recovery 
percentage was estimated on 1 mL of plasma samples spiked 
at three different concentrations (2 µg/mL, 0.3 µg/mL, and 
0.05 µg/mL; six samples per concentration; on three separate 
days), alkalinized with 0.1 N NH
4
OH, and extracted with 
m-tBE, dried under nitrogen, reconstituted in mobile phase, 
and injected onto the chromatograph. Peak areas (extracted) 
were compared to peak areas of identical samples prepared 
by direct dilution of standards at the same concentrations in 
mobile phase and subsequent HPLC analysis. 
 
Extraction efficiency (
Peak Area
Peak Area
extracted
non-ext
%) =
racted
×100.
The ratio was used as a measure of analyte recovery for 
the extraction method. Determination of the LOQ was per-
formed by triplicate injections of standard curves (n=4 on 
four different days) over the range of concentrations tested 
(0.025 µg/mL–8.0 µg/mL) and determining the concentration 
at which the relative standard deviation from the nominal 
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concentration approximated 20%.2 The corresponding 
concentration was taken as the LOQ. The limit of detection 
(LOD) was determined as the lowest plasma concentration 
with a signal-to-noise ratio $3:1.2
Method accuracy was assessed by preparing replicates 
(n=6) of three fortification levels (2.0 µg/mL, 0.3 µg/mL, 
and 0.05 µg/mL of FBZ or OFZ) in 1 mL blank plasma 
on three separate days. These samples were alkalinized, 
extracted, and dried as described for standards and samples. 
The accuracy of the method on a given day was determined 
by comparing the difference in concentration found to the 
nominal concentration added and expressing the result as 
relative standard deviation (%).3
 
Within-day accuracy (%)
FBZ FBZ
FBZ
found added
added
= ×- 100.
The “between-day” method accuracy at three fortification 
levels was determined in a similar fashion, except that the 
difference between the mean of all concentrations on all days 
(n=3 days) was determined and used to calculate difference 
between nominal concentrations of FBZ or OFZ added.3
Method precision between and within days was deter-
mined using analysis of variance (one-way design) and the 
expected between-day and within-day mean squares were 
determined using the following formulae:3
WD precision (%)
MS
FBZ
within-day= ×
[ ]
100
BD precision (%)
MS
[FBZ]
between-day= ×100.
Here, WD represents “within-day,” “BD” indicates 
“between-day,” “MS” represents mean square from the 
analysis of variance table, and [FBZ] is the mean fenbenda-
zole concentration.
Linearity of standard curves, method accuracy, precision, 
extraction efficiency, LOQ, and LOD were determined for 
OFZ in an identical manner.
HPLC–mass spectrometry identification 
of unknown compound based on 
metabolite mass
Plasma samples from animals dosed with single doses of 
FBZ were used to identify an unknown peak, which was 
present at 24 hours, 48 hours, and 96 hours postdosing. 
Extracted samples were repeatedly injected (99 µL), and frac-
tions containing the FBZ, OFZ, and unknown metabolite were 
collected. Each fraction was pooled and reextracted from the 
mobile phase using m-tBE after addition of 0.1 N ammonium 
hydroxide. The ether layer was evaporated to dryness and the 
analyte was resuspended in 200 µL acetonitrile. Reevaluation 
of fractions by injections of FBZ, OFZ, and unknown peak 
on the HPLC demonstrated single peaks, with identical reten-
tion time corresponding to that sample’s identity. The concen-
trated fractions were submitted to the Ohio State University 
Campus Chemical Instrument Center mass spectrometry core 
for confirmation of molecular mass of this fraction.
Briefly, a Micromass LC-Tof™ II mass spectrometer 
equipped with an orthogonal electrospray source (Z-spray) was 
operated in positive ion mode (Micromass, LC-Tof; Waters 
Corporation, Milford, MA, USA). Sodium iodide was used 
for mass calibration over a calibration range of m/z 100–2,000. 
Optimal electrospray ionization (ESI) conditions were capil-
lary voltage 3,000 V, source temperature 110°C, and a cone 
voltage of 55 V. The ESI gas was nitrogen. All ions transmit-
ted into the pusher region of the time-of-flight analyzer were 
scanned over m/z 280–600, with a 1-second integration time. 
Data were acquired in continuum mode during the LC run.
hPlc analysis
The LC/auotsampler system consisted of a Waters Alliance 
2690 Separations Module (Waters, Milford, MA, USA). The 
column used was C
18
, 250×4.6 mm, 5 µm particle size, reverse-
phase column. The mobile phase was altered to 10 mM ammo-
nium acetate, pH 4.0 (35%), and 65% acetonitrile; flow rate 
was maintained at 1 mL/min and was split postcolumn using 
a microsplitter valve (Upchurch Scientific, Oak Harbor, WA, 
USA) to ∼20 µL/min for introduction to the ESI source.
Pharmacokinetic analysis
Zero-time plasma drug concentration intercepts of the bipha-
sic iv disposition curve (A, B) were determined by extrapola-
tion of the plasma fenbendazole concentrations to t=0 for the 
distribution phase (A) and terminal exponential phase (B). 
The hybrid rate constants of the biphasic iv disposition curve 
(α and β) were determined by calculation of the slopes of 
the distribution and elimination phases, respectively. The 
first-order elimination rate constant for disappearance of 
the drug k
10
 from the central compartment was determined 
using the formula
 
k
k10
= α × β
21
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where α and β are the hybrid rate constants for the biphasic 
distribution curve and k
21
 is the rate constant for change 
from the peripheral compartment to central compartment. 
k
12
 and k
21
 are first-order transfer rate constants for drug dis-
tribution between the central and peripheral compartments, 
respectively. These transfer rate constants were calculated 
from the intercepts of the concentration versus time curve, 
with the y axis at time =0 for the distribution phase (A) and 
elimination phase (B), and the hybrid rate constants for the 
biphasic distribution curve (α, β) were determined using the 
following relationships:
k21 =
(A B )
(A B)
× β + × α
+
k k k12 21 10= α + β - × .
The total plasma FBZ clearance was estimated as if it 
were all from the central compartment using the following 
relationship:
 
CL =
IV ( g)
AUCtot
dose
0
µ
→∞
.
Here IV
dose
 is in micrograms and AUC
0→∞ is the area under 
the concentration versus time curve and calculated from the 
zero-time concentrations from the distribution and elimina-
tion phases of the plasma concentration–time curves (A, B) 
and the hybrid rate constants for the biphasic distribution 
curves (α, β) using the following relationship:
 
AUC
B
0→∞ = α
+
β
A
.
The apparent volume of the central (V
1
) and peripheral 
(V
2
) compartments and volume of distribution at steady state 
(V
ss
) were estimated from the equation
 
V1 =
µ
+
IV ( g)
A B
dose
where A + B is the zero-time plasma drug concentrations of 
the disposition phase (A) and elimination phase (B).
Vd
ss
 was calculated by using the equation
 
V V
k k
k
dss = ×
+
1
12 21
21
( )
Distribution half-life (hours) was calculated using the 
formula
 
T1 2 1/ λ =
ln2
α
where ln2 =0.693 and α is the slope of the initial log-linear 
segment of the concentration–time curve. Elimination half-
life was calculated as follows:
 
T1 2/ =
ln2
β
where ln2 =0.693 and β is the slope of the terminal log-linear 
segment of the concentration–time curve.
The area under the first moment of the concentration 
versus time curve (AUMC) from time of dosing to infinity 
was calculated using the following formula:
 
AUMC
A B
2
=
α
+
β2
.
The mean residence time (MRT) was determined from 
the ratio of AUMC to AUC, as follows:
 
MRT
AUMC
AUC
= .
Oral administration data were analyzed by statistical 
moment analysis (noncompartmental analysis or NCA; 
Phoenix WinNonlin Professional (version 6.3); Pharsight 
Corporation, St Louis MO, USA). Data from the 5 mg/kg 
dosing (10% oral suspension; n=5) were individually ana-
lyzed and compared descriptively. Data were modeled using 
model NCA 200 with extravascular input. The parent drug 
(FBZ) was subjected to noncompartmental statistical moment 
analysis to determine terminal elimination rate constant (λ
z
), 
terminal-phase half life (T
1/2λz), maximum plasma concentra-
tion (C
max
), time to maximum plasma concentration (T
max
), 
AUC (extrapolated to infinity), AUMC (extrapolated to infin-
ity), and MRT (extrapolated to infinity). The first-order rate 
constant associated with the terminal log-linear portion of the 
concentration versus time curve λ
z
 (h-1) was calculated from 
individual concentration versus time data using the following 
formula (minimum of final three data points):
 λz = -1( ).slopeelimination
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Half-life of elimination (hours) was calculated using 
standard formulae as follows:
 
HL
ln2
z
z
λ λ
= .
C
max
 and T
max
 were taken directly from the concentration 
versus time data for each animal and time at which maximum 
concentration was found. AUC was calculated using the fol-
lowing formula:
 
AUC n0
1
2-∞
++= ×δ t C Cn .
Here, n is the number of summed trapezoids formed by 
n + 1 trapezoids, C reflects corresponding plasma concentra-
tions; (n, n + 1), tn + 1, and δt represent the change in time 
between these plasma concentrations. AUMC extrapolated 
to infinity is
 
AUMC last last last= + ×δ t t C t C t C C
z z
× × + × +1 1 2 2
22 λ λ
.
MRT extrapolated to infinity was calculated using the 
following formula:
 
MRT
AUMC
AUC
= .
Systemic availability of FBZ was determined using the 
following relationship:
 
F  (%)
AUC
Dose
Dose
PO
IV
IV
PO
= ×AUC
where PO stands for oral administration and IV indicates the 
intravenous mode of administration.
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